Literature DB >> 51832

Specificity of cell-mediated cytotoxicity against human melanoma lines: evidence for "non-specific" killing by activated T-cells.

P Hersey, A Edwards, J Edwards, E Adams, G W Milton, D S Nelson.   

Abstract

The specificity of cell-mediated cytotoxicity against melanoma cells in vitro has been analyzed in a large number of studies with cells both from normal and melanoma subjects. As in a number of other, recent, similar human studies, no evidence for tumour specificity was found. Effector cells in peripheral blood responsible for the cytotoxic raction were examined by cell separation methods based on red cell rosette formation and separation through Hypaque-Ficoll mixtures. The evidence suggests that non-specificity results from killing by cells separating largely in the non-sheep red blood cell rosetting fraction and which have cytotoxic specificity directed broadly to cells with abnormal membranes. Further analysis revealed that the cells were non-phagocytic and did not bear receptors for complement. They appear to be activated into cell division and to bear surface receptors for the Fc portion of IgG. Additional evidence is presented suggesting that the cells mainly responsible are activated thymus-dependent cells present in the circulation of both tumour-bearing and normal subjects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 51832     DOI: 10.1002/ijc.2910160119

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Augmentation of generation of human allospecific cytotoxic T lymphocyte by PPD in in vitro sensitization culture.

Authors:  R Ohno; Y Kodera; H Yamada
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

2.  Identification of lymphocyte subpopulations in E-RFC-enriched and E-RFC-depleted cell fractions of fresh and cryopreserved lymphocytes.

Authors:  R L Bolhuis; H R Schuit
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

3.  Cytotoxic activity of human lymphocyte plasma membranes.

Authors:  J Ferluga; G J Friou; A C Allison
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

4.  Immune status in Crohn's disease. V. Decreased in vitro natural killer cell activity in peripheral blood.

Authors:  I O Auer; E Ziemer; H Sommer
Journal:  Clin Exp Immunol       Date:  1980-10       Impact factor: 4.330

5.  The antibody-independent cytotoxic activity of normal circulating human leucocytes. II. Failure to demonstrate effector cell-target cell interaction and target cell specificity of the circulating cytotoxic-enhancing factor.

Authors:  M Richter; D Banerjee; S Sklar
Journal:  Immunology       Date:  1981-09       Impact factor: 7.397

6.  Alloreactive cytotoxicity of interferon-triggered human lymphocytes detected with tumor biopsy targets.

Authors:  F Vánky; E Klein
Journal:  Immunogenetics       Date:  1982-01       Impact factor: 2.846

7.  Expression of blood group-like antigens on the T lymphocytes of acute leukaemia patients in remission.

Authors:  S Pullen; P Hersey
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

8.  Target selectivity of interferon-induced human killer lymphocytes related to their Fc receptor expression.

Authors:  M G Masucci; G Masucci; E Klein; W Berthold
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

9.  Deficient spontaneous cell-mediated cytotoxicity and lectin-induced cellular cytotoxicity by peripheral blood mononuclear cells from Thai adults naturally infected with malaria.

Authors:  M J Gilbreath; K Pavanand; R P MacDermott; P Phisphumvithi; B Permpanich; T Wimonwattrawatee
Journal:  J Clin Microbiol       Date:  1983-02       Impact factor: 5.948

10.  Immunological consequence of renal transplantation and immunosuppression. I. Alterations in human natural killer-cell activity.

Authors:  W C Waltzer; R J Bachvaroff; A Arnold; D Anaise; F T Rapaport
Journal:  J Clin Immunol       Date:  1985-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.